Prof. Dean Ho is Provost’s Chair Professor, Director of the N.1 Institute for Health (N.1), Director of the Institute for Digital Medicine (WisDM), and Head of the Department of Biomedical Engineering at the National University of Singapore. N.1 is a clinical-stage institute that is pioneering first-in-class interventional trial designs that harness AI to optimise and tailor oncology studies to each patient that is recruited. WisDM is a clinical-stage institute with active studies in digital therapeutics, infectious diseases, and drug development, among others. Both institutes operate at the intersection of technology, clinical innovation, policy, healthcare economics, and behavioural sciences and other domains towards practice-changing advances in medicine.
Using his CURATE.AI platform, Prof. Ho has led multiple pioneering clinical studies that have validated the promise of N.1 medicine, where only a patient’s own data is used to personalize their treatment for the entire duration of care. Multiple CURATE.AI-based clinical studies are ongoing or cleared for start in the areas of solid cancer and blood cancer therapy, digital therapeutics/personalised learning, and post-organ transplant immunosuppression, among others.
Prof. Ho is an elected member of the US National Academy of Inventors (NAI). He is also a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and Society for Laboratory Automation and Screening, as well as a Fulbright Scholar. He is also a recipient of the NSF CAREER Award, Wallace H. Coulter Foundation Translational Research Award, and V Foundation for Cancer Research Scholar Award, among others. Prof. Ho was recently named to the Asia Tatler Gen.T List, which honors leaders who are shaping the future of the region. Prof. Ho has appeared on the National Geographic Channel Program “Known Universe” to discuss his discoveries in drug delivery and imaging. His discoveries have been featured on CNN, The Economist, Forbes, Washington Post, NPR and other international news outlets. He has served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a 26,000+ member global drug development organization comprised of senior executives from the pharmaceutical and medical device sectors, as well as academic thought leaders.